Dr Agarwal’s Healthcare IPO Set to Open Next Week: Rs 3027.26 Crore Issue, Price Band, and Key Details Revealed

Dr Agarwal’s Healthcare, India’s largest eye care hospital chain by revenue, is set to open its initial public offering (IPO) for subscription from January 29 to January 31, 2025. The company, backed by prominent investors TPG and Temasek, has announced its IPO price band, financial goals, and future plans, making it one of the most highly anticipated IPOs of the year.
IPO Overview: Subscription Details and Price Band
Subscriptions for the Dr. Agarwal’s Healthcare IPO will be accepted for three days, from January 29 to January 31. The anchor part will be available on January 28. With a face value of Re 1, the corporation has established the pricing range for its equity shares at between Rs 382 and Rs 402. A minimum of 35 shares, or an initial investment of Rs 14,070, are up for bid by investors.
With Rs 300 crore from the new issue and Rs 2,727.26 crore from the offer for sale, the business is generating a total of Rs 3,027.26 crore through the IPO. A post-money valuation of between Rs 12,700 crore and Rs 12,900 crore is the target for Dr. Agarwal’s Healthcare.
Merger Plans Post-Listing
Dr. Agarwal’s Healthcare has big ambitions to merge with its listed business, Dr. Agarwal’s Eye Hospital, if its shares are listed. The company’s management anticipates that the merger will be finalised within a year following the IPO listing. Currently, the business owns 71.9% of Dr. Agarwal’s Eye Hospital, which was established in 1994.
Although it hasn’t been finalised yet, the merger is a component of the company’s plan to unify its operations under a single organisation. Compliance with relevant legislation, as well as corporate and regulatory clearances, including lender permission and business synergy considerations, will guide this merger process.
Financial Performance and Future Growth
According to its most current financials, Dr. Agarwal’s Healthcare has seen encouraging development. With a total sales of Rs 837.94 crore for the quarter that ended on September 30, 2024, the firm declared a profit after tax (PAT) of Rs 39.56 crore. The business provides a wide range of eye care services, such as consultations, diagnosis, non-surgical treatments, cataract and refractive operations, and the selling of pharmaceuticals, contact lenses, and optical products.
Since its founding in 2010, the business has expanded dramatically, and its initial public offering (IPO) is expected to raise further funds to sustain its growth and expand its presence in the cutthroat eye care sector. The Agarwal family and the leadership team are committed to using their resources and experience to strengthen their position in the industry and provide value to shareholders.
IPO Details: GMP, Allotment, and Listing Date
Based on the top price band of Rs 402, the current Grey Market Premium (GMP) for Dr. Agarwal’s Healthcare IPO is Rs 60, indicating an expected listing price of Rs 462. For prospective investors searching for chances in the IPO market, this is encouraging.
The shares will be launched on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on February 5, 2025, once the IPO’s share allocation is completed on February 3, 2025. Targeting both institutional and individual investors, the IPO is anticipated to generate a lot of interest from investors.
Conclusion: A Strategic Move for Growth
For investors hoping to profit from the expansion of India’s healthcare sector, especially in the eye care sector, Dr. Agarwal’s Healthcare’s initial public offering (IPO) offers an important opportunity. The firm is well-positioned for long-term development because to its impressive financial performance, ambitious merger ambitions, and wide range of services. Investors will have the opportunity to join a well-known healthcare company that has already established itself in the Indian market and is planning to expand even more when the IPO opens.